Clinical Trial Update: Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib [Phase 2]

View source ↗

Summary

Phase 2 study evaluating vemurafenib in combination with fotemustine for patients with V600BRAF-mutant advanced/mutated melanoma who progressed on vemurafenib; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Fotemustine (fotemustine)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Paola Queirolo | Conditions: Malignant Melanoma Stage IV | Phase 2 | Status: COMPLETED